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engineered as well as incidental (e.g., envi-
ronmental) nanoparticles. It is important 
to recognize that from a toxicological per-
spective, there is arguably little distinction 
between engineered and incidental nano-
particles and toxicological understanding 
from one can inform the other.[2] There 
is indeed concern that the development, 
use, and ultimately exposure to MNMs 
could pose a significant risk to humans, 
and such concerns are well founded. This 
is because one only has to look at ambient 
nanoparticles more generally to under-
stand that such adverse health effects are 
occurring in polluted towns and cities on a 
massive scale (see below).
Over the last few decades, such realiza-
tion of the negative impact nanoparticles 
can have on health has led to the avail-
ability of research funding resulting in a 
huge body of high-quality research. The 
combined efforts of material characteriza-
tion, computational modelling, dosimetry, 
in vitro and in vivo models, -omics, expo-
sure, and other disciplines, have advanced our understanding 
markedly. Large-scale projects, such as the European Commis-
sion funded project GRACIOUS,[3] as just one example, are 
now seeking to draw together this information into a science-
based framework that supports effective risk assessment.
However, the vast labyrinth of complex data that has been 
generated by nanotoxicological research also presents some-
thing of challenge in identifying what the next steps will be to 
make significant advances in the field. In their 2015 review,[4] 
Hussain et  al. postulate that nanotoxicology has reached a 
“crossroads” whereby researchers need to build on past achieve-
ments to negotiate the challenges that persistently frustrate 
nanotoxicology research. Key challenges include: rapid pace of 
innovation of new MNMs outstripping the rate of conventional 
safety testing; uncertainty regarding possible exposure 
scenarios, dosimetry, and toxicokinetics; complexities in the 
interactions between nanoparticle physicochemical properties 
and cellular biology; the dynamic nature of nanoparticle 
coronas in biological systems; practicalities in handling nano-
particles and overcoming assay interference; the limited predic-
tivity of current models (both in vitro and in vivo for human 
health effects); and many others.[2,4–17]
2. The Value of Human Data
One additional barrier for MNM research is the paucity of 
human data that combines both metrics of exposure with 
With the ever-expanding number of manufactured nanomaterials (MNMs) 
under development there is a vital need for nanotoxicology studies that test 
the potential for MNMs to cause harm to health. An extensive body of work in 
cell cultures and animal models is vital to understanding the physicochemical 
characteristics of MNMs and the biological mechanisms that underlie 
any detrimental actions to cells and organs. In human subjects, exposure 
monitoring is combined with measurement of selected health parameters in 
small panel studies, especially in occupational settings. However, the availability 
of further in vivo human data would greatly assist the risk assessment of 
MNMs. Here, the potential for controlled inhalation exposures of MNMs in 
human subjects is discussed. Controlled exposures to carbon, gold, aluminum, 
and zinc nanoparticles in humans have already set a precedence to demonstrate 
the feasibility of this approach. These studies have provided considerable insight 
into the potential (or not) of nanoparticles to induce inflammation, alter lung 
function, affect the vasculature, reach the systemic circulation, and accumulate 
in other organs. The need for further controlled exposures of MNMs in human 
volunteers - to establish no-effect limits, biological mechanisms, and provide 
vital data for the risk assessment of MNMs - is advocated.
1. Background
Nanotoxicology is the study of the whether particles or mate-
rials in the nano-scale (with at least one dimension of <100 nm) 
have the potential to cause detrimental actions to cells, organs, 
and organisms.[1] The field of nanotoxicology has grown expo-
nentially over the last two decades, in parallel with develop-
ment of different types of nanoparticles (Figure  1). Whilst 
a significant proportion of the nanotoxicological literature 
addresses manufactured nanomaterials (MNMs), the field of 
nanotoxicology and the application of findings addresses both 
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and repro-
duction in any medium, provided the original work is properly cited.
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relevant health parameters. While there is a reasonable number 
of “real-world” studies of nanoparticle exposure in occupational 
settings (see below) and good mechanistic data from cultured 
human cell lines, there are no large-scale epidemiological 
studies of MNM exposure. This reflects the relative infancy of 
the nanotechnology industry, meaning large-scale production 
(>100 tons per annum) of MNMs and commercial/public use 
for many forms of MNM has not yet occurred. This is very dif-
ferent to the scenario for particulate matter in air pollution, 
which has received considerable attention over the last few dec-
ades. Indeed, air quality has been pushed to prominence on the 
political agenda in most nations across the world. This attention 
has stemmed from staggering estimates of premature mortality 
attributed to ambient PM2.5 (particulate matter with a diameter 
of 2.5 µm or less), which is estimated to be in the magnitude 
of several million early deaths globally every year.[18,19] Addition-
ally, there is now increasing recognition that air pollution has 
detrimental effects on almost all major organs of the body, and 
there now exists an overwhelming body of epidemiological evi-
dence linking exposure to particulate matter with many causes 
of morbidity and mortality.[20,21] Traffic-derived sources are of 
especial concern, due (at least in part) to the high proportion of 
combustion-derived nanoparticles in vehicle exhaust.[22]
Research into the health effects of air pollution is a prime 
example of the value of epidemiological studies in informing 
our understanding of the adverse impact of a certain exposure 
on health, and, therein, to assess current and future risk. In 
the case of MNMs, the goal should be to prospectively prevent 
ill health and so substantial effort is required to confirm nega-
tive results are attributed to effective control measures. For 
statistical power and assessment of potential confounding vari-
ables, epidemiological studies require large cohorts to detect 
relationships between exposures and specific diseases. While 
the nanotechnology sector is a major global industry, the gen-
eral public’s exposure to MNMs is limited at present (although, 
there is always concern that there could be overlooked expo-
sures which have not immediately manifested as health 
concerns due to the prolonged asymptomatic development of 
disease).
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Figure 1. Increasing scientific research on nanotoxicology over the last 20 years. Number of references per year (noncumulative) based on a PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) search for “nanoparticle” (blue dotted line) and “nanotoxicology” (red solid line) without further limits applied. 
The graph highlights that nanotoxicological research has gathered pace over recent years, reflecting the need for toxicological assessment of nanoparticles 
in different settings, including environmental nanoparticles in air pollution, unintentional exposure to manufactured nanomaterials (MNMs) (e.g., 
accidental/occupational exposure), and intentional exposure to MNMs (e.g., in nanomedicine). Use of the broad term “nanoparticle” was used to capture 
all three of these scenarios.
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In the absence of large cohorts of epidemiological data, inves-
tigation of the biological effects of MNMs in human subjects 
would add a hugely valuable perspective to the wealth of mecha-
nistic research in this field and provide an immediate reference 
point for risk assessment. To this end, there have been various 
published studies on human exposure to MNMs addressing 
both incidental and deliberate exposures. Incidental exposure 
includes that resulting from work activities for a (currently) 
limited number of MNMs being produced at commercial 
volumes. As a body of literature, they can provide important 
insight into potential occupational health effects resulting from 
repeated exposures, although such studies can suffer from the 
same issues of limited exposure characterization as well as 
complex and mixed exposure patterns. Deliberate, controlled 
exposures of nanoparticles as part of well-designed studies 
would mitigate against confounding factors found in occupa-
tional investigations. Here, we provide an overview of existing 
evidence for both incidental and controlled exposures to MNMs 
in human subjects.
3. Incidental Occupational Exposures
While epidemiological studies with large cohorts are lacking, 
there are a number of small-scale observational studies of 
MNM exposure and health, especially in occupational settings. 
A review of occupational exposure to nanoparticles is beyond 
the scope here; however, we wish to mention a few examples 
of workplace exposure to noncombustion nanoparticles where 
health parameters have been measured (see also refs. [23,24]). 
The examples below focus on inhalation exposure, and the 
reader is referred elsewhere for other routes of exposure such 
as oral[25,26] and dermal.[27,28]
Several studies have made use of factory floor workers in 
industries producing or packaging MNMs. A study of thirteen 
factories in Taiwan handling a variety of MNMs (including gold, 
silver, iron oxide, titanium dioxide, silicon dioxide, and carbon 
nanotubes) found that exposed workers exhibited reductions 
in lung function. In addition, they found an increase in Clara 
cell protein 16 (a blood marker of airway damage), as well as 
small changes in blood antioxidant and adhesion marker levels, 
compared to workers at the same factories with a lower risk 
of exposure.[29] In another study,[30] even though factory floor 
workers who had handled MNMs (various particles including 
polystyrene, zinc-cadmium, hydroxyapatite, carbon nanotubes, 
copper) did not appear to have a (measurable) greater level of 
exposure in their day-to-day work, they exhibited higher levels 
of several blood cytokines compared to workers who had never 
handled these materials. A number of other comparisons were 
nonsignificant or lacked clarity, perhaps reflecting the diversity 
of exposure dose to multiple materials.
The archetypal carbon nanoparticle, carbon black (CB), is 
used in a number of manufacturing industries, including tyre 
and rubber products, electrical insulating materials, pigments, 
and printer toner. Workers packaging CB in China were found 
to have reduced lung function (by spirometry) and raised levels 
of blood cytokines compared to a control group from a water 
treatment plant in the same city.[31] The investigators state 
that workers wore respiratory protection although the level of 
compliance was not clear. Cross-sectional studies in Iran[32] 
and Nigeria[33] reported similar findings, whereas others in the 
USA[34] and Germany[35] did not find significant associations 
between CB exposure and pulmonary function. Two studies 
have investigated carbon nanotube exposure in an occupational 
setting, finding greater levels of oxidative stress (blood malon-
dialdehyde) in manufacturing workers compared to office 
workers in the same factory.[36] Shvedova et  al., demonstrated 
differential profiles in mRNA and noncoding-RNA (especially 
those linked to the cell cycle, and possibly cardiorespiratory dis-
ease) in workers exposed to CNTs, compared to nonhandling 
workers.[37] Further studies are needed to address biological 
effects to different fiber dimensions and bio-durability of fibers.
Titanium dioxide nanoparticles are one of the most widely 
used MNMs, for applications that include white pigments, sun-
protection cream, and food additives. A cross-sectional study 
of packaging workers in TiO2 nanoparticle manufacturing 
plants in China, found that TiO2 exposure was associated with 
impaired lung function and blood markers of oxidative stress 
and inflammation, and potential predictors of cardiovascular 
disease.[38] Similarly, markers of oxidative stress were increased 
in the exhaled breath condensate of office workers following a 
visit to the factory floor of a TiO2 factory.[39,40]
Other metal-rich nanoparticles have been a subject of con-
cern due, among other things, to their potential to induce 
health effects through oxidative stress. It has been recognized 
that metal welders have a higher relative risk of cardiovascular 
morbidity and mortality.[41,42] Ellingsen et  al. made a compar-
ison of 72 welders with suitable referents from similar occupa-
tions. Welders were estimated to have exposures of 8.1 mg m−3 
during their working day, and accordingly were found to have 
higher levels of inflammatory (TNF-alpha) and pro-thrombotic 
biomarkers (P-selectin, CD40L, pro-thrombin, D-dimers) in the 
blood.[43] Similarly, volunteers that had been asked to spend sev-
eral hours in settings with exposure to welding fumes exhibited 
a variety of inflammatory responses in the lung and blood.[24] 
Other occupational exposures of metal particles, such as steel 
plant or iron foundry workers, or occupations with exposure to 
particulates rich in aluminum or manganese, have shown indi-
cations of depressed anti-inflammatory respiratory defences, 
and possibly even neurological symptoms.[24,44]
While these occupational studies provide a useful insight 
into selected human populations, often there are as many 
negative findings as positive ones, and this may reflect study 
limitations or confounding variables, for example, lack of an 
optimum comparative control group, the mixture of nanopar-
ticles the person is exposed to, poor characterization of expo-
sure (time and concentration) between individuals, the need to 
stratify for smoking status, and occupational confounders such 
as high temperatures, strenuous activity, etc.
4. Nanomedicines
Nanoparticle exposure is not only an occupational issue, nor is 
exposure only incidental/accidental. Due to the unique prop-
erties of nanoparticles, MNMs offer many opportunities to 
provide benefits to a wide range of sectors. One example with 
immediate relevance to human health, is the development 
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of MNMs for purposeful administration to people for drug 
delivery or diagnostic agents in medical imaging.[45] For 
example, ultra-small paramagnetic iron oxide nanoparticles 
(SPIONs; with a diameter between 10–40 nm) have been tested 
clinically as potential alternatives to contrast agents such as 
gadolinium for magnetic resonance imaging (MRI). Using 
this imaging modality, SPIONs are being considered for uses 
that include cell tracking, identification of cancerous growths 
or visualization of cardiac blood vessels to assess coronary 
artery disease. The advantage of SPIONs is that, after injection, 
these particles localize to areas of inflammation and, therefore, 
could reveal tissues that are actively developing diseases, or 
trigger points in disease pathophysiology such as the inflamed 
“unstable” atherosclerotic plaques in blood vessels that could 
trigger a cardiovascular event such as a heart attack or stroke. 
As an example, Richards et  al. demonstrated that it was pos-
sible to label peripheral blood monocytes with SPIONs without 
overtly activating the cells, allowing them to be re-administered 
to the volunteer by intramuscular injection.[46] The investiga-
tors demonstrated that after injection the SPION-laden cells 
relocated to subcutaneous areas that had been experimentally 
inflamed. The group have since gone on to test the feasibility 
and value of SPIONs in patients with myocardial ischaemia[47] 
and abdominal aortic aneurysm.[48] Despite the high concen-
trations of intravenous solutions administered, these agents 
appear to have good biocompatibility and seemingly little 
toxicity. However, the full extent of the cellular effects of dif-
ferent SPION suspensions after uptake by inflammatory cells 
(or other cell types), and potential to induce complement 
hypersensitivity reactions,[49] deserves further attention. This is 
especially true after chemical modification of the particles, for 
example, to increase stability, improve biokinetics, or influence 
the cellular target of the SPION.
In terms of nanotherapeutics, these must go through 
the same regulatory approval process as any new medicinal 
product or medical device (nanomaterials may fall into either 
category dependent on the mode of action). Whilst the spe-
cific approvals process differs between regulatory bodies, the 
process understandably requires a high degree of testing to 
ensure safety and efficacy. Such testing typical requires a com-
bination of in vivo studies as well as phased clinical trials in 
humans; a combination not required in other regulatory envi-
ronments. It is applications that have much lower testing 
requirements or fall out with current legislation that raise 
concerns about possible health effects. The rigorous testing 
required before new nanotherapeutics can progress to market 
is welcome and will allow the unique benefits of these mate-
rials to be fully realized.
5. Controlled Exposures in Human Volunteers
A study approach that has been employed with great success 
in the field of air pollution is that of “controlled exposure” in 
human volunteers (Figure 2). In these studies, volunteers are 
asked to inhale a specified test material/pollutant at a carefully 
regulated concentration in a “controlled” setting (e.g., in an 
exposure chamber or through a facemask), with ready access 
to clinical experience and facilities for measurement of health 
parameters and as a safeguard for unforeseen adverse events. 
This approach has a number of advantages such as the “expo-
sure” being administered by a physiologically relevant route 
(i.e., inhalation, with breathing rate often regulated by use of 
mild/moderate exercise on a stationary bicycle or treadmill). 
Exposures can be tightly controlled to ensure they are identical 
between subjects with specific materials/pollutants adminis-
tered in isolation (e.g., gases can be separated from particles, or 
particles can be size-segregated) to determine causative constit-
uents of complex exposure sources. Many of the confounders 
of epidemiological studies can be removed or controlled, such 
as exposure to vehicle exhaust without traffic noise, or avoiding 
uncertain fluctuations in stress from driving in traffic, etc. 
Repeated visits (with treatments randomized between volun-
teers) can also be used to account for other confounding vari-
ables and allow volunteers to act as their own controls (e.g., one 
visit with exposure to the pollutant, a second visit uses filtered 
air exposure with the same conditions, with exposure type ran-
domized). Furthermore, a wider range of health parameters can 
be measured that may not be practical in real world settings or 
gathered during more routine occupational health monitoring. 
Specific patient subgroups with defined health conditions can 
also be recruited to participate in exposures under clinical 
supervision to further understand effects in sensitive groups.
Controlled exposure studies have been used to assess 
the biological actions of environmental nanoparticles, espe-
cially combustion-derived nanoparticles in vehicle exhaust. 
The potential health effects of diesel exhaust (DE) have been 
explored using 2 h exposures to diesel exhaust diluted to levels 
that could be encountered on very heavily congested roads 
(usually 100–300 µg particulate m−3). Several groups have used 
this approach to demonstrate the potential for DE to induce 
a range of health effects. These include localized effects such 
Figure 2. Controlled inhalation exposures in human volunteers. Left and middle panel: Exposure chamber for diesel exhaust exposures in Umea Uni-
versity, Sweden. Images courtesy of Prof Thomas Sandstrom and Prof Anders Blomberg. Right panel: volunteer in the University of Edinburgh Clinical 
Research Facility, where vascular responses are being measured by forearm plethysmography. Image courtesy of Prof Nicholas Mills.
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as bronchoconstriction and increased airway resistance,[23,50,51] 
pulmonary inflammation,[23,52–59] and oxidative stress,[50,55,60] 
DNA methylation in bronchial biopsies or blood cells,[61,62] and 
exacerbation of allergic responses[63] as well as reductions in 
parameters related to exercise capacity.[64] Systemic effects have 
also been analyzed such as inflammation[52,65–67] and oxidative 
stress,[68–70] increased levels of circulating oxidized lipopro-
tein receptors,[71] increased blood pressure,[72] impaired vas-
cular function (arterial contraction),[73,74] reduced  vasodilator 
responses,[75–79] increased arterial stiffening,[80] promotion 
of blood clotting,[69,81] and increased cardiac ischaemia[82] 
(Figure 3). Experiments that removed the particulate fraction 
of DE using experimental filtering or exhaust particle traps[83,84] 
demonstrated that it was the particulate constituents of DE that 
drive cardiovascular impairments. This approach has subse-
quently been used to investigate other environmentally relevant 
particles such as wood-smoke particles (e.g., refs. [85–88]) and 
exhaust from biodiesel fuels.[89–91] These approaches have been 
invaluable in demonstrating the targets and mechanisms by 
which combustion-derived nanoparticles promote cardiorespi-
ratory disease.
There are a few isolated studies that have performed con-
trolled exposure to MNMs in human volunteers. Our group 
investigated which constituents of DE were responsible for 
cardiovascular impairment using a four-visit study design with 
exposures to i) DE, ii) filtered air, iii) filtered-DE, and iv) Palas 
spark-generated carbon particles (Figure 4).[84] The latter group 
was used to assess the effects of a “clean” carbon nanoparticle to 
compare to that of the more chemically complex diesel exhaust 
particle (which can be viewed as a carbon core with a complex 
surface chemistry containing transition metals and a vast array 
of organic carbon species). Due to the smaller size of the Palas 
generated particles, identical mass concentrations could not 
be reached (70 µg m−3 for Palas; 348 µg m−3 for DE), however, 
the Palas exposure contained double the particle numbers 
(3 865 000 vs 1 198 000 for DE) and presumably a greater sur-
face area dose. While DE impaired vascular function, neither 
the Palas particles nor the DE devoid of particles, alter vascular 
responses. It was concluded that the complex surface constitu-
ents of DE particles were responsible for driving the vascular 
effects of DE in humans. These findings have parallels with 
that of an earlier human exposure study using lower concentra-
tions of carbon nanoparticles (10–50 µg m−3; 30–40 nm count 
median diameter) which also found only subtle or no effects 
on lung function, exhaled nitric oxide or sputum biomarkers.[93] 
From the viewpoint of manufactured nanoparticles, the result 
is intriguing and will help inform the debate as to whether 
“pure” carbon nanoparticles, such as carbon black pose a risk to 
health. While they are generally not considered as high-toxicity 
materials, rodent studies have clearly shown that nanosized 
carbon particles are far from completely inactive, being able to 
instigate both oxidative stress and inflammation.[94–97] However, 
such effects are often seen at very high doses associated with 
lung overload with considerable debate as to whether or not 
such effects are species specific and therefore of relevance to 
humans.[96]
Controlled human exposures of MNMs have also been used 
to address the possibility of particle translocation from the lung 
to the systemic circulation. While there is now considerable 
evidence in animals that inhaled nanoparticles cross into the 
blood to reach other organs (see [98]), prior to 2006 there was 
only an isolated study investigating whether a similar process 
occurred in human subjects. Nemmar et  al. performed inha-
lation of Technegas in healthy volunteers. Technegas contains 
99mTc-labeled carbon particles of 5–10  nm primary diameter, 
that can be detected at very low concentrations by using a 
gamma counter.[99] The investigators detected radioactivity in 
the blood of volunteers a minute after inhalation, with levels 
reaching a maximum in the blood at 10–20  min and contin-
uing to increase in the liver over 60 min. However, subsequent 
studies by separate groups[100,101] failed to replicate these find-
ings. While radioactivity could be detected in the blood of Tech-
negas-exposed subjects, thin layer chromatography suggested 
that the blood signal arose from the soluble pertechnetate label 
rather than particulates,[100] and thus re-opened the question as 
to whether particles per se can translocate to the blood in man.
Recently, our group reassessed particle translocation in 
human subjects using gold nanoparticles (Figure  5).[102] Gold 
offers a range of advantages over other model particles: i) the 
substance is relatively inert and safe for human administra-
tion, ii) gold nanoparticles can be synthesized in a range of 
sizes, including those within the primary size range of DE, 
iii) the body should contain negligible levels of gold basally 
(unlike carbon), and iv) a number of extremely sensitive tech-
niques are available to detect gold at the low levels occurring 
in systemic organs after translocation. Following inhalation of 
spark-generated gold nanoparticles (4 nm primary size, 19 nm 
aerodynamic diameter) in healthy volunteers (2 h at 116 µg m−3  
during intermittent moderate exercise), gold could be measured 
Figure 3. Controlled exposure to diesel exhaust impairs cardiovascular 
function. Schematic of the time course of the multiple cardiovascular 
e!ects of acute exposure to diesel exhaust. Reproduced with permis-
sion.[92] Copyright 2012, The Author, published by Future Medicine LTD 
(part of Future Science Group).
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in the blood within the 24 h after exposure. Interestingly, gold 
was still found in the blood of these volunteers three months 
after the exposure. Heat-fusing of gold nanoparticles allowed 
larger particles to be synthesized (34  nm primary diameter, 
52  nm aerodynamic diameter). On inhalation, the smaller 
4  nm diameter gold nanoparticles more readily entered the 
blood and was found in the urine, compared the larger 34 nm 
particles. Lastly, patients were recruited that had a history of 
cerebral ischaemia (stroke) due to the build-up of inflamed 
atherosclerotic plaques in their carotid arteries. A small 
number of volunteers were willing to inhaled gold nano-
particles (4 nm) on the day prior to their surgery to remove the 
diseased plaque from the arteries. Raman spectromicroscopy 
was used to demonstrate the accumulation of gold in the 
diseased tissue that was removed. The ramifications of these 
findings have been discussed previously[98,102] but, if nothing 
else, these studies demonstrate that it is possible to perform 
exposures to manufactured nanomaterials in both healthy 
volunteers and patient groups, if using low-toxicity materials in 
carefully controlled and ethically performed clinical studies.
There are only a very small number of exposure studies 
to MNMs in controlled (nonoccupational) settings. Firstly, 
Sikkeland et al. carried out 2 h inhalation to aluminum oxide par-
ticles (≈4  mg m−3, 3  nm primary diameter) in 15 healthy male 
students.[103] The exposure caused a modest increase in levels 
of interleukin-8 in the volunteers’ sputum, without significant 
Figure 4. Controlled exposure of diesel exhaust compared to “clean” Palas carbon nanoparticles. a) Schematic of exposure chamber for a comparison 
of exposures of clean air, diesel exhaust, filtered diesel exhaust, or Palas carbon nanoparticles. b) Characteristics of four exposures. c) Diesel exhaust, 
but not Palas particles impaired forearm vascular responses (increasing forearm blood flow with infusion of the vasodilator bradykinin). Schematic and 
data in (a) and (b) and graph in (c) for diesel exhaust: Reproduced with permission.[84] Copyright 2011,The Authors, Published by European Society of 
Cardiology. Graph of Palas data: previously unpublished.
Small 2020, 2001516
www.advancedsciencenews.com www.small-journal.com
2001516 (7 of 12) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
changes in neutrophils or levels of matrix metalloproteinase 
(MMP)-8 compared to the sham exposure (clean air). Secondly, 
exposure to nanoparticle-rich welding fumes (1 mg m−3 intermit-
tently for 3 s every 20  min for 5.5 h) in a chamber setting led 
to mild increases in IL-6 in the nasal lavages of welders without 
lower airways symptoms, whereas there were no significant 
changes in lung function or blood biomarkers.[104] To the best of 
our knowledge, we are aware of only a two sets of experiments 
that have performed inhalation exposures to a MNM of poten-
tially greater toxicity (excluding combustion-derived particle 
studies), both using zinc oxide nanoparticles.[105–108] Beckett et al. 
carried out controlled exposure to 0.5  mg m−3 ZnO nanoparti-
cles (≈40 nm count median diameter) in healthy volunteers, and 
found no effect on subject-reported symptoms, cardioelectrophys-
iology (heart rate variability) or blood markers of inflammation 
or coagulation.[105] In contrast, Monsé et al. performed controlled 
exposure to higher doses of ZnO nanoparticles (Figure  6). Six-
teen healthy volunteers inhaled ZnO nanoparticles (≈10 nm pri-
mary diameter) for 4 h at a dose of 0.5, 1 or 2 mg m−3. Inhalation 
of ZnO caused a concentration-dependent increase in systemic 
inflammation (C-reactive protein, serum amyloid-A, and blood 
neutrophils) and the highest dose caused mild flu-like symptoms 
in some volunteers.[107] The exposure also caused airway inflam-
mation and symptoms of irritation, although the effects were not 
concentration-dependent.[108] There was no indication of oxidative 
stress (F2α-isoprostane levels) in the sputum, but matrix metal-
loproteinase-9 (MMP-9) levels were increased. The findings pro-
vided valuable information to inform the setting of occupational 
levels of zinc nanoparticles. Exposure limits for ZnO are set at 
5–10  mg m−3 in many countries,[109] yet these controlled expo-
sure studies suggested that a No Observed Adverse Effect Level 
(NOAELs) is likely to be a magnitude smaller than this in the 
case of the nanosized materials. It should be noted that factors 
such as level of activity of participants, particle size, and, impor-
tantly, solubility of the metal oxide nanoparticles, is likely to have 
an impact on the biological response and subsequent NOAELs.
Finally, in the interests of completeness, we should also 
acknowledge that there are a number of controlled human 
Figure 5. Controlled exposure of gold nanoparticles for the exploration of particle translocation. a) Inhalation of gold nanoparticles through a facemask 
by an exercising volunteer. b) Detection of gold in the blood and urine of participants by inductively coupled plasma mass spectrometry. c) Greater 
translocation of small (4 nm) versus large (34 nm) nanoparticles. d) Detection of gold particles (yellow, orange, and red colors; Raman microspectros-
copy) in the atherosclerotic plaque removed from stroke patients following carotid endarterectomy. Reproduced under the terms of the ACS Editors’ 
Choice with CC-BY license (https://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html).[102] Copyright 2017, American Chemical Society.
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exposures to nanoparticles via the dermal route.[110–112] These 
studies tend to investigate TiO2 and ZnO due to their use in 
sun-protection creams. One such example was that of Gulson 
et  al.[112] who studied the dermal penetration of two different 
sizes (≈20  nm and >100  nm) of ZnO nanoparticles enriched 
with the stable isotope 68  Zn. The material was incorporated 
into sunscreen formulations and applied to the backs of human 
volunteers twice a day for 5 consecutive days. Little 68 Zn was 
detected in blood and urine in the subsequent 6 days suggesting 
that the overwhelming majority of applied nano particles were 
not absorbed. The use of human volunteers was valuable to 
overcome interspecies differences in skin properties, such as 
thickness and follicular density, and the setting in which the 
study was conducted (sunscreens were applied to humans 
undergoing normal activities at a beach) further demonstrates 
the utility of human studies to address complex scenarios that 
cannot be fully replicated in animal models.
6. Limitations of Human Controlled  
Exposure Studies
Controlled human studies provide the opportunity to establish 
a better understanding of the effects of MNM on human health 
without waiting for widespread exposures to occur. They can 
be seen as a proactive, rather than reactive, approach that helps 
mitigate some of the uncertainty caused by the paucity of more 
comprehensive epidemiological data. Furthermore, they have clear 
benefits over the use nontarget species models such as rodents 
that could exhibit different physiological responses and sensitivi-
ties to MNMs. Additionally, they can help extrapolate our under-
standing of the data outputs from the in vivo and, possibly, in vitro 
evidence base for more effective hazard and risk assessment. How-
ever, controlled human exposures, like any model, have their own 
limitations that need to be understood in order to make the most 
of such a powerful tool and avoid misinterpretation of findings.
Figure 6. Controlled exposure to zinc oxide nanoparticles. a) Inhalation of ZnO nanoparticles led to a concentration-dependent increased in inflamma-
tion (CRP = C-reactive protein; SAA = serum amyloid-A). Data are presented as a ranked score from 0 (no change) to 4 (maximum change), with shaded 
numbers representing increases in values and unshaded numbers representing decreases. b) All tested concentrations of ZnO led to increased bio-
markers of inflammation (neutrophils; IL-8 = interleukin-8; total protein; IL-6 = interleukin-6), matrix metalloproteinase (MMP-9), and tissue-inhibitors 
of metalloproteinase (TIMP-1) in sputum (presented as a score of ranks). Reproduced under the terms of the CC-BY Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/).[107] Copyright 2018, The Authors, published by BioMed Central (part of Springer 
Nature). Reproduced under the terms of the CC-BY Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/
by/4.0/).[108] Copyright 2019, The Authors, published by BioMed Central (part of Springer Nature).
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One limitation is in understanding the nature of a detected 
response in terms of adversity and the wider disease pathway. 
Put simply, it is unethical to harm someone and, therefore, 
human-exposure studies will always be limited in terms of the 
severity and duration of effect. Quite rightly, ethical approval is 
unlikely to be forthcoming for exposure of participants to poten-
tially hazardous materials, for example, certain forms of long 
carbon nanotubes known to cause mesothelioma in rodents.[113] 
Furthermore, the levels of exposure allowed are likely to be lim-
ited to levels associated with minimal health risks and, subse-
quently, necessitate the use of sensitive techniques to measure 
more subtle changes in biomarkers or health parameters. Addi-
tionally, the majority of human controlled exposure studies 
use healthy volunteers (although not all, e.g., refs. [23,82]) due 
to logistical difficulties in enrolling patients and the inherent 
risks of using susceptible individuals. Many patients will 
usually be taking medication, which adds an additional factor 
of uncertainty and may even directly the inhibit the pathways 
of nanoparticle action that are under investigation. Cessation of 
medication is rarely ethically acceptable. In this regard, cellular 
and animal models of disease offer a valuable tool to study the 
actions of nanoparticles in diseased processes.
Another important factor is that controlled exposures are 
inevitably acute in nature. It is both impractical and ethically 
questionable to repeatedly expose participants to test substances 
over chronic or even sub-acute periods. Instead, exposures tend 
to be isolated and for relatively short durations (e.g., 1 h to 
6 h) with sufficient recovery or washout periods (usually at least 
two weeks, ideally more) between participant exposure visits. 
As such, controlled human exposures may not address the pos-
sible cumulative effects arising after repeated exposures, or 
adaptive responses to exposures. Thus, controlled human expo-
sure studies tend to focus on early, transient effects in order to 
make judgments as to possible long-term disease outcomes by 
considering possible adverse outcome pathways within the con-
text of the wider toxicology test model landscape.
Lastly, studies in humans have principally focused on res-
piratory and selected cardiovascular parameters, with the use of 
blood and urine biochemistry to assess effects on other organ 
systems. Given the growing appreciation that inhaled nano -
particles can access the systemic circulation,[114,115] and the aware-
ness of the multi-organ effects of particles in air pollution,[20,21] 
it will be important to further address MNM toxicity in other 
organs.[116] Studies in animals and cells will be extremely valu-
able in this regard, due to the availability of tissues that can be 
harvested and the ability to clarify mechanisms in specific cell 
types in isolation.
7. Concluding Remarks
Continued research in nanotoxicology is essential to assess the 
potential risk of exposure to MNMs and ultimately establish a 
safe-by-design approach to the development of new MNMs to 
maximize the unique properties of these materials. As we enter a 
new decade of nanotoxicological research, it will be important to 
ensure that future research progresses at a rate that keeps up with 
the commercial development of MNMs. Given the large amount 
of effort, time, and funding that have already taken place, it will 
be important to make sure that research ensures that relevant 
materials are tested not only in commonly-employed founda-
tion assays, but also newer approaches that offer greater mecha-
nistic insight and more relevance to human exposure scenarios. 
It is the authors’ opinion that there is a need for more studies 
using carefully designed controlled exposure in human subjects. 
While this may not be ethically feasible for high-toxicity mate-
rials, a precedent has already been set for human nanoparticle 
exposures in the field of air pollution and with isolated studies 
with inhalation of low-to-moderate toxicity MNMs. This is par-
ticularly the case for materials of high commercial interest that 
may proceed to use in society, and those materials where there 
is a greater risk of human contact through occupational or acci-
dental exposure. Human data is not a prerequisite for risk assess-
ment. Studies in animal models, cell cultures, and other in vitro 
assays have been vital to our understanding of nanoparticles in 
the body; generating valuable complementary data to the limited 
human data currently available and establishing crucial mode-of-
action pathways that would not have been possible from human 
studies alone. Indeed, the great efforts and valuable information 
obtained by preclinical nanotoxicology has already played a fun-
damental role is establishing informative nanosafety platforms 
and risk assessment tools. However, we feel that the addition of 
controlled human exposures studies would make a vital adjunct 
to existing methods and significant next step in nanotoxicological 
research.
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